Auteur/autrice : GRECC

The Rapid Rise in Investment in Psychedelics— Cart Before the Horse

The Rapid Rise in Investment in Psychedelics— Cart Before the Horse Joshua PHELPS, Ravi N. SHAH, Jeffrey A. LIEBERMAN, JAMA Psychiatry, 2022, 79, (3), 189-190. Doi : 10.1001/jamapsychiatry.2021.3972   Anticipating a renaissance, many psychedelic medicine companies have conducted initial public offerings, where in private companies first issue news hares of stock for sale to the public, making the companies publicly traded entities.1 As of this writing, there are more than 50 publicly traded companies related to the development or administration of psychedelic like drugs in the US, with at least 3 valued at more than $1 billion. The market for psychedelic substances is projected to [...]

Lire la suite

OTC Cannabidiol Products Tied to Improved Pain, Sleep, Anxiety, Liz Scherer, Medscape.com, 2022

OTC Cannabidiol Products Tied to Improved Pain, Sleep, Anxiety Liz Scherer https://www.medscape.com/viewarticle/967088?uac=292598PZ&faf=1&sso=true&impID=4065214&src=mkm_ret_220305_mscpmrk_neuro_pain Medscape Medical News © January 24, 2022   Over-the-counter cannabidiol (CBD) products appear to improve pain, sleep, and anxiety disorders, preliminary research suggests. Interim findings from the Advancing CBD Education and Science (ACES), a 100% virtual, open label, randomized controlled trial, show study participants experienced various degrees of "clinically meaningful" improvements in sleep quality, anxiety, and pain. “ACES is the largest clinical trial ever conducted on commercially available CBD products and provides first-of-its-kind real world evidence into what conditions users may experience benefit from CBD usage, whether these benefits are clinically meaningful, what attributes of CBD [...]

Lire la suite

Cannabis in the management of PTSD : a systematic review, Yasir Rehman et al., 2021

Cannabis in the management of PTSD : a systematic review, Yasir Rehman, Amreen Saini, Sarina Huang, Emma Sood, Ravneet Gill and Sezgi Yanikomeroglu AIMS Neuroscience, 2021, 8, (3), 414-434. Doi : 10.3934/Neuroscience.2021022   Abstract : Introduction : Existing reviews exploring cannabis effectiveness have numerous limitations including narrow search strategies. We systematically explored cannabis effects on PTSD symptoms, quality of life (QOL), and return to work (RTW). We also investigated harm outcomes such as adverse effects and dropouts due to adverse effects, inefficacy, and all-cause dropout rates. Methods : Our search in MEDLINE, EMBASE, PsycInfo, CINAHL, Web of Science, CENTRAL, and PubMed databases, yielded 1 eligible RCT and 10 [...]

Lire la suite

Endocannabinoid System as Therapeutic Target of PTSD : A Systematic Review, Luca Steardo, Jr. et al., 2021

Endocannabinoid System as Therapeutic Target of PTSD : A Systematic Review Luca Steardo, Jr., Elvira Anna Carbone, Giulia Menculini, Patrizia Moretti, Luca Steardo and Alfonso Tortorella Life, 2021, 11, 214. Doi : 10.3390/life11030214 Abstract : Post-Traumatic Stress Disorder (PTSD) is a complex disorder involving dysregulation of stress-related hormones and neurotransmitter systems. Research focused on the endocannabinoid system (eCBS) for anxiety and stress regulation, cognitive and emotional responses modulation and aversive memories extinction, leading to the hypothesis that it could represent a possible alternative treatment target for PTSD. In this systematic review, we summarize evidence about the efficacy and safety of medicinal cannabidiol (CBD), D9-tetrahydrocannabinol (D9-THC), and [...]

Lire la suite

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review, Laura Orsolini et al., 2019

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review Laura Orsolini, Stefania Chiappini, Umberto Volpe, Domenico De Berardis, Roberto Latini, Gabriele Duccio Papanti  and John Martin Corkery Medicina, 2019, 55, 525, 1-14 doi : 10.3390/medicina55090525 www.mdpi.com/journal/medicina Abstract : Background and Objectives : Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives [...]

Lire la suite

Circulating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity : heterogeneity in a community-based cohort, Terri A. deRoon-Cassini et al., 2022

Circulating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity : heterogeneity in a community-based cohort Terri A. deRoon-Cassini, Carisa L. Bergner, Samantha A. Chesney, Nicholas R. Schumann, Tara Sander Lee, Karen J. Brasel and Cecilia J. Hillard Translational Psychiatry, 2022, 12, 48, 1-12. Doi : 10.1038/s41398-022-01808-1   The endocannabinoid signaling system (ECSS) regulates fear and anxiety. While ECSS hypoactivity can contribute to symptoms of established post-traumatic stress disorder (PTSD), the role of the ECSS in PTSD development following trauma is unknown. A prospective, longitudinal cohort study of 170 individuals (47% non-Hispanic Caucasian and 70% male) treated at a level 1 trauma [...]

Lire la suite

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique, Dr Christian SUEUR, GRECC, version 3-5, mars 2022

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, GRECC, version 3-5 Dr Christian SUEUR, mars 2022 112 pages       Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1]   En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout en précisant [...]

Lire la suite

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects, Friederike Holze et al., 2022

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects Friederike Holze, Laura Ley, Felix Müller, Anna M. Becker, Isabelle Straumann, Patrick Vizeli, Sebastian Silva Kuehne, Marc A. Roder, Urs Duthaler, Karolina E. Kolaczynska, Nimmy Varghese, Anne Eckert and Matthias E. Liechti Neuropsychopharmacology, 2022, 1-8. Doi : 10.1038/s41386-022-01297-2 Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double blind, randomized, placebo-controlled, [...]

Lire la suite

Cannabis is indigenous to Europe and cultivation began during the Copper or Bronze age: a probabilistic synthesis of fossil pollen studies, John M. McPartland et al., 2017

Cannabis is indigenous to Europe and cultivation began during the Copper or Bronze age: a probabilistic synthesis of fossil pollen studies John M. McPartland · Geoffrey W. Guy · William Hegman Vegetation History and Archaeobotany, 2018, 27, 635–648 Doi : 10.1007/s00334-018-0678-7   Abstract Conventional wisdom states Cannabis sativa originated in Asia and its dispersal to Europe depended upon human transport. Various Neolithic or Bronze age groups have been named as pioneer cultivators. These theses were tested by examining fossil pollen studies (FPSs), obtained from the European Pollen Database. Many FPSs report Cannabis or Humulus (C/H) with collective names (e.g. Cannabis/Humulus or Cannabaceae). To dissect these aggregate [...]

Lire la suite

Chemical and Morphological Phenotypes in Breeding of Cannabis sativa L., Gianpaolo Grassi and John M. McPartland, 2017

Chemical and Morphological Phenotypes in Breeding of Cannabis sativa L. Gianpaolo Grassi and John M. McPartland in S. Chandra et al. (eds.), Cannabis sativa L. - Botany and Biotechnology, Chapter 6, 2017, 137-160. Doi : 10.1007/978-3-319-54564-6_6   Abstract This chapter has two parts. The first part details five characters that contribute to phenotypic diversity in Cannabis. Cannabinoids can be assayed by quantity (dry weight percentage of cannabinoids in harvested material) or by quality (the THC/CBD ratio, or chemotype). Cannabinoid quality is largely genetic, possibly monogenic. We dissect the monogenic inheritance model (two alleles at a single gene locus). Essential oil is composed of volatile, aromatic terpenoids. [...]

Lire la suite